

Award Number: W81XWH-12-1-0236

TITLE: EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer

PRINCIPAL INVESTIGATOR: Billy W. Loo, Jr., M.D., Ph.D

CONTRACTING ORGANIZATION: ~~U.S. Army~~ University
Stanford CA 94305-2004

REPORT DATE: September 2014

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE UNCLASSIFIED	2. REPORT TYPE Annual Report	3. DATES COVERED 15 OCT 2013 - 14 OCT 2014
4. TITLE AND SUBTITLE EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer		5a. CONTRACT NUMBER
		5b. GRANT NUMBER W81XWH-12-1-0236
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S) Billy W. Loo, Jr., M.D., Ph.D E-Mail: BWLoo@Stanford.edu	5d. PROJECT NUMBER	
	5e. TASK NUMBER	
	5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Stanford University Stanford CA 94305-2004		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		
13. SUPPLEMENTARY NOTES		

14. ABSTRACTPurpose and scope:

Stereotactic ablative radiotherapy (SABR) has become a new standard of care for early stage lung cancer in patients who are not candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segment of patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greater proportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients having comorbidities that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especially expected to affect very short courses of radiation as in SABR. Imaging using a third generation hypoxia PET agent, ¹⁸F-EF5, is a promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting.

Our objectives are (1) to understand the prevalence of hypoxia detectable by imaging in early stage NSCLC; (2) to validate ¹⁸F-EF5 PET as an indicator of tumor oxygenation status in this patient population; and (3) to evaluate ¹⁸F-EF5 PET as a prognostic imaging biomarker for local primary tumor control after SABR.

Progress, results, and major findings:

All institutional and DOD human subjects approvals are complete and current. We have now accrued and completed all study procedures on 11 patients out of the planned total accrual of 43 patients. All scans have been successfully acquired with good technical quality, and follow-up is currently up-to-date for all enrolled patients.

Per the protocol, a planned preliminary analysis was conducted on the scan data from the first 5 patients. In order to inform the remainder of the current study, we conducted a preliminary analysis including four additional previous patients from a parallel study in our department who meet the eligibility requirements of the current study. Preliminarily, with respect to the primary endpoint, 3 of 5 patients (6 of 9 including the parallel study patients) had imageable hypoxia as defined by our plan of analysis. With respect to the endpoint of imaging response to tumor oxygenation perturbation, 2 of 3 patients (4 of 6 including the parallel study patients) with initially positive EF5 scans had the expected imaging response to carbogen. 1 of 2 patients (1 of 3 including the parallel study patients) with an initially negative EF5 scan had the expected imaging response to DCA. Follow up is ongoing for the endpoint of local primary tumor control, but is too short to assess this endpoint meaningfully.

An action plan is in place to increase patient accrual according to the originally planned schedule.

Significance:

In summary, our preliminary findings suggest the presence of tumor hypoxia even in relatively small, early stage lung cancer. Additional validation of this finding is pending completion and analysis of our study. Because tumor hypoxia is a strong mechanism of radioresistance, particularly for hypofractionated courses of radiation as in SABR, if validated this finding has substantial implications for the optimal application of SABR to early stage lung cancer. EF5-PET imaging could be useful as a risk stratification factor for clinical trials of lung cancer SABR, and could ultimately be used to individualize therapy for patients with early stage lung cancer.

15. SUBJECT TERMS NOTHING LISTED

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	9	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	2
Body.....	2
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	5
References.....	6
Appendices.....	6

INTRODUCTION:

Stereotactic ablative radiotherapy (SABR) has become a new standard of care for early stage lung cancer in patients who are not candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segment of patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greater proportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients having comorbidities that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especially expected to affect very short courses of radiation as in SABR. Imaging using a third generation hypoxia PET agent, ^{18}F -EF5, is a promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting. Our objectives are (1) to understand the prevalence of hypoxia detectable by imaging in early stage NSCLC; (2) to validate ^{18}F -EF5 PET as an indicator of tumor oxygenation status in this patient population; and (3) to evaluate ^{18}F -EF5 PET as a prognostic imaging biomarker for local primary tumor control after SABR. If accomplished, these would lay the foundation for future prospective therapeutic clinical trials using ^{18}F -EF5 PET as a stratification factor, and ultimately to individualize therapy.

BODY:

Initiation of this project was initially delayed in response to revisions requested by the DOD human subjects review process. We received the approval memorandum from DOD to start the project on February 13, 2013. The period covered by this report is February 2013 to September 2014, corresponding to project months 1-18 in the Statement of Work. The tasks in the Statement of Work pertaining to project months 1-18 and the progress on each are described below.

A. Progress on Statement of Work by task (only tasks for months 1-18 included)

Task 0. Pre-award preparation (4 months prior to award)


- 0a. Application for Stanford institutional review board (IRB) and scientific review committee (SRC) approval (4 months)
- 0b. Recruitment of clinical research coordinator (2 months prior to award)

Status: Completed during pre-award period.

All institutional and DOD human subjects and SRC approvals are complete and current. A clinical research coordinator is in place.

Task 1. Patient recruitment (months 1-24)

We received the approval memorandum from DOD to start the project on February 13, 2013. Prior to this we obtained all the required IRB and FDA approvals and recruited a clinical research coordinator (*Task 0*). As such, Quarter 8 represents months 16-18 of the project timeline. During the past quarter, we screened 5 patients and enrolled 1. This brings the total accrual to 9 patients to date, compared to a projected 30 patients (see Figure 1).



Of note, our patient screening rate (i.e., identification of eligible patients) very closely parallels the projected accrual rate. The discrepancy between screening and accrual reflects primarily patient willingness to accept the logistical challenges of completing two non-standard-of-care EF5-PET scans, mostly because of the time commitment and long distance traveled by a large proportion of our patients.

Task 2. Patient follow-up (months 4-34)

Task 2a. Completion of case report forms at each follow-up visit: Follow-ups are complete to date for the enrolled patients, though it is still relatively early for most of the patients. Scheduled follow-up imaging is at 3-month intervals post-SABR. Four patients have had four follow-up scans, four have had two scans, and one has had two. There has been no evidence of local recurrence in any patient at this point. One patient, unfortunately, recently passed away.

Task 2b. Review of data from first 5 patients (months 3-5). The study team will assess any technical barriers to collecting all the required imaging data for the first 8 patients, and address deficiencies if necessary: **All of the first five patients each successfully completed two EF5 PET scans prior to SABR. Synthesis of ¹⁸F-EF5 was consistently reliable with good yield, and there were no technical barriers to scan acquisition or maneuvers to modify oxygenation (carbogen breathing or DCA administration). In addition, there were no technical barriers encountered for any of the subsequent patients to date.**

Task 2c. Semi-annual internal data review (every 6 months). The study team will internally audit all data collected on the study to ensure complete collection of study endpoints including imaging data. Missing information will be reconciled: **Collection of all imaging and clinical data has been reviewed and is current to date.**

Task 3. Data analysis (months 4-36)

Task 3a. Preliminary analysis of ¹⁸F-EF5 PET imaging data from first 5 patients (months 3-5). We will evaluate the image quality and technical adequacy to perform all the quantitative analysis specified by the protocol. We will also assess whether modifications to the software are needed to streamline and automate data analysis, and implement the improvements: We have preliminarily analyzed the EF5-PET imaging data from the first 5 patients. The results are summarized below.

Task 3b. Preliminary analysis of ¹⁸F-EF5 PET imaging data from first 20 patients (months 13-15). We will perform quantitative image analysis to ensure the ability to collect all the intensity histogram and volumetric data. Statistical analysis of the results will not be performed until completion of all data collection: We have not yet accrued 20 patients. This analysis will be done when sufficient patients have been accrued.

3c-3g (scheduled for project months 19-36)

B. Preliminary analysis of data to date

The preliminary results for the first 5 accrued patients are provided in Table 1.

Pt	Histology	Stage – Location	TMR1	Hypoxic	Intervention	TMR2	Hypoxic	Change	Expected
1	Adeno	IA – LLL	1.19	Yes	Carbogen	1.31	Yes	↑	↓
2	SCC	IA – LLL	1.95	Yes	Carbogen	1.39	Yes	↓	↓
3	SCC	IA – RUL	0.65	No	DCA	0.63	No	↓	↑
4	Adeno	IA – RUL	0.70	No	DCA	0.86	No	↑	↑
5	NSCLC	IA – LUL	1.28	Yes	Carbogen	1.11	Yes	↓	↓

Table 1. Abbreviations: Adeno = adenocarcinoma; SCC = squamous cell carcinoma; NSCLC = non-small cell lung cancer, not otherwise specified; LLL = left lower lobe; LUL = left upper lobe; RLL = right lower lobe; RML = right middle lobe; TMR = tumor: muscle EF5 uptake ratio; Yes = TMR significantly > 1; DCA = dichloroacetate

Of note, we have been conducting a parallel study of EF5-PET imaging with a very similar design, but for a much broader population of patients with different tumor primary sites, histologies, and stages. Prior to the initiation of the current project, four patients enrolled on our parallel study met the inclusion criteria of the current study and had the same study procedures (i.e., early stage NSCLC treated with SABR, with two pre-treatment EF5 scans and tumor oxygenation perturbation intervention as per the current study). As such, a preliminary analysis including these patients is presented here in Table 2 as it is relevant to the current study.

Histology	Stage – Location	TMR1	Hypoxic	Intervention	TMR2	Hypoxic	Change	Expected
Adeno	IA – LUL	1.53	Yes	Carbogen	1.07	Yes	↓	↓
SCC	IB – RLL	0.66	No	DCA	0.54	No	↓	↑
Adeno	IA – RLL	1.16	Yes	Carbogen	1.05	Yes	↓	↓
Adeno	IB – RML	1.45	Yes	Carbogen	1.66	Yes	↑	↓

Table 2. Data from previous patients in parallel study meeting eligibility criteria for current study

Preliminarily, with respect to the primary endpoint, 3 of 5 patients (6 of 9 including the parallel study patients) had imageable hypoxia as defined by our plan of analysis. With respect to the endpoint of imaging response to tumor oxygenation perturbation, 2 of 3 patients (4 of 6 including the parallel study patients) with initially positive EF5 scans had the expected imaging response to carbogen. 1 of 2 patients (1 of 3 including the parallel study patients) with an initially negative EF5 scan had the expected imaging response

to DCA. Follow up is ongoing for the endpoint of local primary tumor control, but is too short to assess this endpoint meaningfully.

KEY RESEARCH ACCOMPLISHMENTS:

- All human subjects approvals obtained
- Scans of good technical quality
- 28 patients screened, 9 enrolled; follow up current to date
- Preliminarily, analysis of the first 5 patients as well as 4 similar patients from a parallel study in our department suggest promise

REPORTABLE OUTCOMES:

None to date.

Publication of results (Task 4 of Statement of Work) is scheduled for project months 30-36.

CONCLUSIONS: Summarize the results to include the importance and/or implications of the completed research and when necessary, recommend changes on future work to better address the problem. A "so what section" which evaluates the knowledge as a scientific or medical product shall also be included in the conclusion of the report.

The preliminary analysis to date supports the hypothesis that a substantial proportion of patients with early stage non-small cell lung cancer have tumor hypoxia that can be detected by EF5-PET imaging. A more detailed image analysis is ongoing to optimize the quantitation of tumor EF5 uptake. This includes evaluating the stability of uptake in the background regions between the serial scans and whether the background in muscle or the mediastinal blood pool may be a more appropriate reference; evaluating the sensitivity of region of interest delineation to lesion size and partial volume effects and if so, approaches for mitigating these effects.

With respect to the endpoint of being able to detect a change in tumor oxygenation status after interventions expected to perturb tumor oxygenation, additional patients will need to be studied to assess whether there is a statistically significant effect. Similarly, longer clinical follow up will be required to assess correlation of EF5 uptake with local primary tumor control.

Based on the number of eligible patients screened, we anticipate that our patient volume will be sufficient to complete this study. However, clearly a substantial barrier to patient enrollment is the logistical challenge of coming for two extra appointments to receive the two EF5-PET scans. Particularly because SABR offers a much shorter treatment course than conventional radiation therapy, similar to surgery that involves a short course of treatment, patients are coming for treatment from a large geographic region. Extra trips present a significant burden to these patients.

Action plan: To address this issue, we will modify our workflow to combine the EF5-PET scan dates with existing appointments, such as pre-treatment appointments for radiation therapy simulation or pulmonary function testing. We anticipate that this should be possible for the majority of patients and would eliminate this consistent barrier to enrollment. This would require no modification to the clinical trial protocol. We will also

expand our efforts to screen patients from other thoracic oncology clinics outside of Radiation Oncology. Since we have encountered no other barriers, and have been able to complete all scans with good technical quality and have had complete patient follow-up to date, we expect this action plan to help bring us back into alignment with the originally planned study timeline.

In summary, our preliminary findings suggest the presence of tumor hypoxia even in relatively small, early stage lung cancer. Additional validation of this finding is pending completion and analysis of our study. Because tumor hypoxia is a strong mechanism of radioresistance, particularly for hypofractionated courses of radiation as in SABR, if validated this finding has substantial implications for the optimal application of SABR to early stage lung cancer. EF5-PET imaging could be useful as a risk stratification factor for clinical trials of lung cancer SABR, and could ultimately be used to individualize therapy for patients with early stage lung cancer.

REFERENCES:

None to date.

APPENDICES:

None.